23 February 2023
Avacta Group plc
("Avacta" or the "Group" or the "Company")
Avacta Therapeutics Division Science Day
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is today holding a Science Day, focused on its Therapeutics Division, for institutional investors and analysts as stated in the announcement on the 19 December 2022.
No material new information will be disclosed as part of this meeting.
The event will include a detailed review of the ongoing ALS-6000-101 Phase 1a clinical trial of AVA6000, Avacta's lead pre|CISION™ tumour targeted form of the chemotherapy drug Doxorubicin, in soft tissue sarcoma, as well as an update on preclinical programmes.
There will also be presentations from two outstanding key opinion leaders in the field of oncology, Professor Krishna KomanduriChief, Division of Hematology and Oncology, Dept. of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, University of California San Francisco, USAand Dr William TapChief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
A copy of the presentations given at the Science Day will be made available on the Group's website, along with a full recording of the day, within 24 hours of the end of the meeting.
-Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications Director
Tel: +44 (0) 1904 21 7070
Stifel Nicolaus Europe Limited(Nomad and Broker)
Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown
Tel: +44 (0) 207 710 7600
FTI Consulting (Financial Media and IR)
Simon Conway / Alex Shaw
Tel: +44(0) 203 727 1000
Zyme Communications(Trade and Regional Media)
Lily Jeffery
Tel: +44 (0)7891 477 378
About Avacta Group plc - https://www.avacta.com
Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.
Avacta'sTherapeutics Division , a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre|CISION™ tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.
The Affimer® platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.
The pre|CISION™ tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION™ modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.
Avacta'sDiagnostics Division develops and supplies a broad range of in-vitro diagnostic (IVD) solutions. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer® platform to differentiate immunodiagnostic products to provide marketing leading performance.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDMSCDBGDDGXDDGXD
==